Tyra Biosciences, Inc. TYRA
21.76
(0.65)
(2.90%)
as of 25 Sep
- Market cap
- $1.5B
- P/E
- 0.0×
Follow TYRA
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.02 | 8.22 | 84.09 | 45.13 | 13.80 | 23.81 | 14.67 |
Net Debt/EBITDA |
— | (0.05) | 1.65 | 11.56 | 4.28 | 2.56 | 3.29 | 1.94 |
Debt/Assets |
0.00% | 47.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (0.05) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.64 | 0.83 | 0.90 | 0.91 | 0.73 | 0.81 | 0.79 |
Capex/Depreciation |
— | 0.00 | (6.64) | (4.61) | (1.89) | (2.16) | (1.28) | (0.26) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 44.24% | 101.59% | (18.25%) | (19.77%) | (29.92%) | (31.60%) | (39.83%) | |
| — | (1,539.77%) | (112.90%) | (16.30%) | (19.31%) | (28.10%) | (29.34%) | (37.13%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (556.67%) | (6,300.84%) | (3,807.64%) | (2,614.25%) |
Return on Tangible Assets |
— | 85.54% | (68.05%) | (8.72%) | (21.90%) | (34.92%) | (25.85%) | (48.24%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.06) | (5.24) | (1.77) | (1.21) | (1.19) | (1.23) | (1.60) |
Cash per Share |
— | 0.00 | 9.87 | 21.93 | 6.00 | 4.76 | 5.97 | 4.30 |
Shareholders Equity per Share |
— | (0.11) | (8.84) | 21.90 | 6.16 | 4.78 | 6.00 | 4.35 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.11) | (8.84) | 21.90 | 6.16 | 4.78 | 6.00 | 4.35 |
Free Cash Flow |
— | (2.62) | (8.07) | (24.39) | (50.84) | (50.91) | (70.44) | (95.28) |
Working Capital |
— | (5.03) | 13.42 | 300.44 | 251.59 | 196.34 | 332.87 | 247.36 |
Capital Expenditures |
— | (0.02) | (0.31) | (0.64) | (0.56) | (0.77) | (0.66) | (0.14) |
Net Current Asset Value |
— | (5.14) | (14.37) | 299.09 | 248.94 | 190.08 | 327.06 | 242.02 |
| Other line items | ||||||||
Quick Ratio |
— | 0.02 | 8.19 | 83.57 | 44.06 | 13.27 | 23.40 | 14.15 |
Depreciation/Fixed assets |
— | 0.03 | 0.16 | 0.14 | 0.27 | 0.22 | 0.31 | 0.42 |
Cash ROIC |
— | 66.07% | (508.20%) | (4.10%) | (10.09%) | (12.70%) | (10.43%) | (18.72%) |
Accounts Payable Turnover |
— | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 14,919.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.06) | (5.03) | (1.72) | (1.20) | (1.17) | (1.22) | (1.60) |
Capex per Share |
— | 0.00 | (0.20) | (0.05) | (0.01) | (0.02) | (0.01) | 0.00 |
Average Payables |
— | 0.50 | 0.50 | 0.63 | 0.87 | 2.90 | 2.63 | 0.88 |
Average Assets |
— | 0.26 | 8.27 | 161.36 | 286.44 | 246.02 | 294.71 | 323.08 |
Average Common Equity |
— | (9.19) | (9.19) | 144.05 | 279.78 | 231.05 | 273.71 | 301.16 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates